MIRA (Mira Pharmaceuticals) ROC (Joel Greenblatt) %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIRA Mira Pharmaceuticals Inc MIRA
13 GF Score
Price $0.96
! 1 Warning Sign
View Full Analysis

What is Mira Pharmaceuticals ROC (Joel Greenblatt) %?

Mira Pharmaceuticals MIRA +2.81% 13 ROC (Joel Greenblatt) % is 0.00% as of Mar. 2026. GuruFocus rates MIRA with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 983 Drug Manufacturers companies, Mira Pharmaceuticals ranks worse than 98.98% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Mira Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Mira Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:

MIRA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -160360   Med: -4621.14   Max: -1936.26
Current: -18473.58

During the past 5 years, Mira Pharmaceuticals's highest ROC (Joel Greenblatt) % was -1936.26%. The lowest was -160360.00%. And the median was -4621.14%.

MIRA's ROC (Joel Greenblatt) % is ranked worse than
98.98% of 983 companies
in the Drug Manufacturers industry
Industry Median: 11.46 vs MIRA: -18473.58

Mira Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Mira Pharmaceuticals  (NAS:MIRA) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Mira Pharmaceuticals ROC (Joel Greenblatt) % Related Terms


Mira Pharmaceuticals ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Mira Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mira Pharmaceuticals ROC (Joel Greenblatt) % Chart

Mira Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
0.00 -1,936.26 -4,621.14 -160,360.00 0.00

Mira Pharmaceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13,622.64 -11,667.92 0.00 0.00 0.00

MIRA vs NSRX, SCLX, MDCX: ROC (Joel Greenblatt) % Comparison

For the Drug Manufacturers - General subindustry, Mira Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mira Pharmaceuticals ROC (Joel Greenblatt) % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mira Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Mira Pharmaceuticals's ROC (Joel Greenblatt) % falls into.


MIRA
13GF Score
Mira Pharmaceuticals Inc MIRA
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mira Pharmaceuticals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.028) - (0.702 + 0 + 0)
=-0.674

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.021000000000001) - (0.034 + 0 + 0.081)
=-0.093999999999999

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Mira Pharmaceuticals for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-4.412/( ( (0 + max(-0.674, 0)) + (0 + max(-0.093999999999999, 0)) )/ 1 )
=-4.412/( ( 0 + 0 )/ 1 )
=-4.412/0
= %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 0.00% mean?
Mira Pharmaceuticals (MIRA) has a ROC (Joel Greenblatt) % of 0.00% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Mira Pharmaceuticals and its competitors. According to the industry distribution chart, Mira Pharmaceuticals ranks #973 out of 983 companies in the Drug Manufacturers industry, placing it in the top 99%.
Is Mira Pharmaceuticals' ROC (Joel Greenblatt) % too high?
Mira Pharmaceuticals' current ROC (Joel Greenblatt) % is 0.00%. Based on the distribution chart, Mira Pharmaceuticals ranks #973 out of 983 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mira Pharmaceuticals has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Mira Pharmaceuticals' ROC (Joel Greenblatt) % compare to NSRX and SCLX?
According to the Drug Manufacturers industry distribution chart, Mira Pharmaceuticals ranks #973 out of 983 companies for ROC (Joel Greenblatt) %. This places Mira Pharmaceuticals in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Mira Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mira Pharmaceuticals's current ROC (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mira Pharmaceuticals stock overvalued right now?
Mira Pharmaceuticals (MIRA) has a current ROC (Joel Greenblatt) % of 0.00%. The current ROC (Joel Greenblatt) % is 0.00%. Mira Pharmaceuticals' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Mira Pharmaceuticals (MIRA), the current ROC (Joel Greenblatt) % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mira Pharmaceuticals Business Description

Address 1200 Brickell Avenue, Suite 1950 No. 1183, Miami, FL, USA, 33133
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
13GF Score

Get the complete analysis for MIRA

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.96
Price